Department of Biochemistry, Maisonneuve-Rosemont Hospital Research Centre, University of Montreal, Montreal H1T 2M4, Quebec, Canada.
Department of Ophthalmology, Maisonneuve-Rosemont Hospital Research Centre, University of Montreal, Montreal H1T 2M4, Quebec, Canada.
Aging (Albany NY). 2020 Dec 23;12(24):24836-24852. doi: 10.18632/aging.202404.
MicroRNAs are small non-coding RNAs that post-transcriptionally regulate gene expression. We recently demonstrated that levels of miR-106b were significantly decreased in the vitreous and plasma of patients with neovascular age-related macular degeneration (AMD). Here we show that expression of the miR-106b-25 cluster is negatively regulated by the unfolded protein response pathway of protein kinase RNA-like ER kinase (PERK) in a mouse model of neovascular AMD. A reduction in levels of miR-106b triggers vascular growth both and by inducing production of pro-angiogenic factors. We demonstrate that therapeutic delivery of miR-106b to the retina with lentiviral vectors protects against aberrant retinal angiogenesis in two distinct mouse models of pathological retinal neovascularization. Results from this study suggest that miRNAs such as miR-106b have the potential to be used as multitarget therapeutics for conditions characterized by pathological retinal angiogenesis.
微小 RNA 是一类小的非编码 RNA,可对基因表达进行转录后调控。我们最近发现,新生血管性年龄相关性黄斑变性(AMD)患者的玻璃体和血浆中 miR-106b 的水平显著降低。在这里,我们展示了在新生血管性 AMD 的小鼠模型中,蛋白激酶 RNA 样内质网激酶(PERK)的未折叠蛋白反应途径负调控 miR-106b-25 簇的表达。miR-106b 水平的降低通过诱导促血管生成因子的产生,分别在 和 触发血管生长。我们证明,用慢病毒载体将 miR-106b 递送到视网膜中,可以防止两种不同的病理性视网膜新生血管化的小鼠模型中的视网膜异常血管生成。这项研究的结果表明,像 miR-106b 这样的 miRNA 有可能被用作具有病理性视网膜血管生成特征的疾病的多靶点治疗药物。